

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S.No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Rs in Mn)	Value of transaction during the reporting period (Rs in Mn)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
53	Lupin Limited		Novel Laboratories Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on their behalf recovered	8.2	8.2									
54	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on their behalf recovered	9.0	9.0									
55	Lupin Limited		Laboratorios Grin S.A. de CV, Mexico		Wholly-Owned Subsidiary	Expenses incurred on their behalf recovered	5.0	5.0									
56	Lupin Limited		Lupin Healthcare Limited, India		Wholly-Owned Subsidiary	Expenses incurred on their behalf recovered	5.7	5.7									
57	Lupin Limited		Lupin Digital Health Limited, India		Wholly-Owned Subsidiary	Expenses incurred on their behalf recovered	12.8	12.8									
58	Lupin Limited		Lupin Healthcare Limited, India		Wholly-Owned Subsidiary	Reversal of Interest provided earlier	Refer Note 3	Refer Note 3									
59	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly-Owned Subsidiary	Services Received (Expense)	25.2	25.2									
60	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Services Received (Expense)	64.9	64.9									
61	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Services Received (Expense)	39.8	39.8									
62	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly-Owned Subsidiary	Services Received (Expense)	45.4	45.4									
63	Lupin Limited		Lupin Healthcare UK Limited, UK		Wholly-Owned Subsidiary	Services Received (Expense)	61.0	61.0									
64	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Services Received (Expense)	185.1	185.1									
65	Lupin Limited		Lupin Research Inc., USA		Wholly-Owned Subsidiary	Purchase of Goods	98.0	98.0									
66	Lupin Limited		Lupin Research Inc., USA		Wholly-Owned Subsidiary	R & D expenses paid	242.0	242.0									
67	Lupin Limited		Novel Laboratories Inc., USA		Wholly-Owned Subsidiary	R & D Expenses paid	15.8	15.8									
68	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	8.5	8.5									
69	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	17.0	17.0									
70	Lupin Limited		Lupin Research Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	22.1	22.1									
71	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	4.1	4.1									
72	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	10.1	10.1									
73	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	11.6	11.6									
74	Lupin Limited		Generic Health Pty Limited, Australia		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	Refer Note 4	Refer Note 4									
75	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	96.7	96.7									
76	Lupin Limited		Lupin Europe GmbH, Germany		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	3.1	3.1									
77	Lupin Limited		Novel Laboratories Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.1	0.1									
78	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	1.6	1.6									
79	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.4	0.4									
80	Lupin Limited		S. N. Pharma		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods and services	44.5	44.5									
81	Lupin Limited		Shuban Prints		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods and services	27.6	27.6									
82	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Investment	380.3	380.3								Business Purpose	
83	Lupin Limited		Lupin Digital Health Limited, India		Wholly-Owned Subsidiary	Investment	220.0	220.0								Business Purpose	
84	Lupin Limited		Lupin Healthcare Limited, India		Wholly-Owned Subsidiary	Investment	500.0	500.0								Business Purpose	

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.						
S.No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Rs in Mn)	Value of transaction during the reporting period (Rs in Mn)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure
85	Lupin Limited		S. N. Pharma		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Services Received (Expense)	26.0	26.0								
86	Lupin Limited		S. N. Pharma		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Expenses incurred on our behalf reimbursed & Other Reimbursements	2.1	2.1								
87	Lupin Limited		Team Lease Services Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Services Received (Expense)	21.1	21.1								
88	Lupin Limited		Zyma Properties Pvt. Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Rent Paid	20.0	20.0								
89	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly-Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	648.1	648.1								
90	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Withdrawal of corporate guarantees given by the Company to the bankers of subsidiary company	365.6	365.6								
91	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly-Owned Subsidiary	Withdrawal of corporate guarantees given by the Company to the bankers of subsidiary company	700.1	700.1								
92	Lupin Limited		Nanomi B.V., Netherlands		Wholly-Owned Subsidiary	Guarantees issued by the Company on behalf of subsidiary company for contractual obligations	1,550.7	1,550.7								
93	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly-Owned Subsidiary	Guarantees issued by the Company on behalf of subsidiary company for contractual obligations	64.6	64.6								
94	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly-Owned Subsidiary	Receivables	-	-	339.6	248.4						
95	Lupin Limited		Multicare Pharmaceuticals Philippines Inc, Philippines		Subsidiary	Receivables	-	-	41.0	52.5						
96	Lupin Limited		Lupin Philippines Inc., Philippines		Wholly-Owned Subsidiary	Receivables	-	-	220.5	270.7						
97	Lupin Limited		Novel Laboratories Inc., USA		Wholly-Owned Subsidiary	Receivables	-	-	3.9	5.8						
98	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Receivables	-	-	2,583.9	6,842.5						
99	Lupin Limited		Generic Health Pty Limited, Australia		Wholly-Owned Subsidiary	Receivables	-	-	288.8	264.4						
100	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly-Owned Subsidiary	Receivables	-	-	153.2	173.7						
101	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly-Owned Subsidiary	Receivables	-	-	3.8	10.6						
102	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly-Owned Subsidiary	Receivables	-	-	15,866.4	12,801.7						
103	Lupin Limited		Lupin Research Inc., USA		Wholly-Owned Subsidiary	Receivables	-	-	31.5	30.9						
104	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly-Owned Subsidiary	Receivables	-	-	350.5	374.3						
105	Lupin Limited		Lupin Atlantis Holding SA, Switzerland		Wholly-Owned Subsidiary	Receivables	-	-	301.0	245.5						
106	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly-Owned Subsidiary	Receivables	-	-	191.9	356.3						
107	Lupin Limited		Laboratorios Grin S.A. de CV, Mexico		Wholly-Owned Subsidiary	Receivables	-	-	0.4	2.7						
108	Lupin Limited		Lupin Europe GmbH, Germany		Wholly-Owned Subsidiary	Receivables	-	-	0.1	0.2						
109	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Receivables	-	-	538.7	812.6						
110	Lupin Limited		Lupin Healthcare Limited, India		Wholly-Owned Subsidiary	Receivables	-	-	5.4	5.1						
111	Lupin Limited		Nanomi B.V., Netherlands		Wholly-Owned Subsidiary	Receivables	-	-	7.7	7.8						
112	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly-Owned Subsidiary	Receivables	-	-	Refer Note 5	Refer Note 6						
113	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Receivables	-	-	15.5	3.1						
114	Lupin Limited		Lupin Digital Health Limited, India		Wholly-Owned Subsidiary	Receivables	-	-	-	1.3						
115	Lupin Limited		Lupin Biologics Limited, India		Wholly-Owned Subsidiary	Receivables	-	-	0.2	0.2						
116	Lupin Limited		Generic Health Pty Limited, Australia		Wholly-Owned Subsidiary	Payables	-	-	0.8	0.6						
117	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly-Owned Subsidiary	Payables	-	-	22.2	32.0						
118	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly-Owned Subsidiary	Payables	-	-	26.4	40.7						
119	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly-Owned Subsidiary	Payables	-	-	18.9	11.3						
120	Lupin Limited		Lupin Europe GmbH, Germany		Wholly-Owned Subsidiary	Payables	-	-	2.0	2.6						
121	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly-Owned Subsidiary	Payables	-	-	25.7	47.9						
122	Lupin Limited		Lupin Inc., USA		Wholly-Owned Subsidiary	Payables	-	-	78.8	35.5						
123	Lupin Limited		Lupin Management Inc., USA		Wholly-Owned Subsidiary	Payables	-	-	94.6	96.5						
124	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly-Owned Subsidiary	Payables	-	-	67.4	30.1						
125	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly-Owned Subsidiary	Payables	-	-	1,228.1	717.1						
126	Lupin Limited		Lupin Philippines Inc., Philippines		Wholly-Owned Subsidiary	Payables	-	-	-	0.1						
127	Lupin Limited		Lupin Research Inc., USA		Wholly-Owned Subsidiary	Payables	-	-	300.2	291.4						

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.						
S.No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Rs in Mn)	Value of transaction during the reporting period (Rs in Mn)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure
202	Lupin Atlantis Holdings SA, Switzerland		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	5.0								
203	Lupin Atlantis Holdings SA, Switzerland		Nanomi B.V., Netherlands		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	1.3								
204	Lupin Atlantis Holdings SA, Switzerland		Lupin Inc., USA		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	247.1								
205	Nanomi B.V., Netherlands		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	Refer Note 8								
206	Nanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	9.1								
207	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	0.5								
208	Lupin Inc., USA		Novel Laboratories Inc., USA		Fellow Subsidiary	Interest income on Inter-corporate Loans	NA	14.8								
209	Multicare Pharmaceuticals Philippines Inc., Philippines		Lupin Philippines Inc., Philippines		Fellow Subsidiary	Rent Received	NA	0.2								
210	Multicare Pharmaceuticals Philippines Inc., Philippines		Lupin Philippines Inc., Philippines		Fellow Subsidiary	Purchase of Goods	NA	48.1								
211	Generic Health Pty Limited, Australia		Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Purchase of Goods	NA	0.2								
212	Generic Health Pty Limited, Australia		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Services Received (Expense)	NA	Refer Note 9								
213	Lupin Atlantis Holdings SA, Switzerland		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	70.8								
214	Lupin Atlantis Holdings SA, Switzerland		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Services Received (Expense)	NA	15.4								
215	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Services Received (Expense)	NA	175.1								
216	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharmaceuticals Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	0.7								
217	Lupin Atlantis Holdings SA, Switzerland		Lupin Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	9.9								
218	Lupin Atlantis Holdings SA, Switzerland		Lupin Management Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	25.8								
219	Lupin Atlantis Holdings SA, Switzerland		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	0.1								
220	Lupin Atlantis Holdings SA, Switzerland		Lupin Europe GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	21.6								
221	Lupin Atlantis Holdings SA, Switzerland		Lupin Research Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	0.1								
222	Nanomi B.V., Netherlands		Lupin Management Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	6.8								
223	Nanomi B.V., Netherlands		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	2.3								
224	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	1.2								
225	Yt. Biologies Ltd., Japan		Lupin Atlantis Holdings SA, Switzerland		Jointly Controlled Entity	Services Received (Expense)	NA	7.1								
226	Lupin Atlantis Holdings SA, Switzerland		Lupin Research Inc., USA		Fellow Subsidiary	R & D expenses paid	NA	25.8								
227	Nanomi B.V., Netherlands		Lupin Research Inc., USA		Fellow Subsidiary	R & D expenses paid	NA	68.1								
228	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Service Charges received	NA	23.2								
229	Generic Health Pty Limited, Australia		Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Receivable			0.1							
230	Lupin Pharmaceuticals Inc., USA		Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Receivable		1.1	1.0							
231	Lupin Pharmaceuticals Inc., USA		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Receivable		(0.6)	171.0							
232	Lupin Research Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivable		18.8	39.9							
233	Lupin Research Inc., USA		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Receivable		7.1	14.9							
234	Lupin Inc., USA		Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Receivable		0.1	0.1							
235	Lupin Inc., USA		Lupin Oncology Inc., USA		Fellow Subsidiary	Receivable		8.4	1.1							
236	Lupin Inc., USA		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Receivable		3.2	6.5							
237	Lupin Management Inc., USA		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Receivable		4.4	24.3							
238	Lupin Management Inc., USA		Multicare Pharmaceuticals Philippines Inc., Philippines		Fellow Subsidiary	Receivable		6.5	6.4							
239	Lupin Management Inc., USA		Laboratorios Grin S.A. de CV, Mexico		Fellow Subsidiary	Receivable		15.8	13.4							
240	Lupin Management Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivable		4.5	3.9							

Details of Related Parties transactions during the period October 1, 2021 to March 31, 2022.

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																		
S.No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Rs in Mn)	Value of transaction during the reporting period (Rs in Mn)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
315	Nanomi B.V., Netherlands		Lupin Research Inc., USA		Fellow Subsidiary	Payables			18.8	39.9								
316	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Payables			3.6	5.7								

- Notes:**
- 1) Receivables / Payables represents combined balance against Sales / Purchase of Goods and debit / credit notes pertaining to various services / reimbursement of expenses. Hence shown separately.
 - 2) The value of transaction is Rs 6,995
 - 3) The value of transaction is Rs (41,667)
 - 4) The value of transaction is Rs (7,053)
 - 5) The value of closing balance is Rs 35,318
 - 6) The value of closing balance is Rs 3,518
 - 7) The value of closing balance is Rs 23,078
 - 8) The value of closing balance is Rs 23,803
 - 9) The value of transaction is Rs 43,107
 - 10) The value of closing balance is Rs 32,661
 - 11) The value of closing balance is Rs 6,632